Cyre2067
The Living Force
Hey all, recently I had a friend mention this company, 23andme to me and the services they provide. It's kinda cool, you spit in a jar and mail it to them and they sequence your DNA for virtually every known marker of disease susceptibility and resistance. Carrier status on some crazy number of disease genes, ancestory via haplogroups, even percentage of neanderthal genes you retain.
It sounds like an interesting way to acquire some self-knowledge, but I'm a bit hesitant to have my DNA on file and the data owned by some company. It's not terribly expensive, $99 is the one-time fee and they keep updating it as new genes are marked. Apparently if you're distantly related to someone else in their database of like 150,000 people then they'll let you know.
I thought I'd bring it up here and see what everyone thought before going forward.
_https://www.23andme.com/
Edit: Here's their investors:
They say the right things on Privacy:
and this lady seems to be the head honcho:
It sounds like an interesting way to acquire some self-knowledge, but I'm a bit hesitant to have my DNA on file and the data owned by some company. It's not terribly expensive, $99 is the one-time fee and they keep updating it as new genes are marked. Apparently if you're distantly related to someone else in their database of like 150,000 people then they'll let you know.
I thought I'd bring it up here and see what everyone thought before going forward.
_https://www.23andme.com/
Edit: Here's their investors:
_https://www.23andme.com/about/corporate/
Investors
The company has received Series A, B, and C funding from several prominent technology and health science companies, strategic angel investors and venture capital firms, including Johnson & Johnson Development Corporation (NYSE: JNJ); MPM Capital, The Roche Venture Fund (Swiss: RO.SW ), Google Ventures (NASDAQ: GOOG), and New Enterprise Associates, among others.
Google Ventures seeks to discover and help develop great companies — we believe in the power of entrepreneurs to do amazing things. Our investments range from seed to late stage, across a broad range of industries, including consumer Internet, software, hardware, clean tech, biotechnology and health care. We embrace the challenge of helping young companies grow from the proverbial garage to global relevance. The Google Ventures team includes entrepreneurs, investors and innovators, along with some 23,000+ exceptional Googlers whose breadth of knowledge, experience and creativity constitute perhaps our most valuable resource. For more information, visit www.google.com/ventures.
New Enterprise Associates (NEA) is a leading venture capital firm focused on helping entrepreneurs create and build major new enterprises that use technology to improve the way we live, work and play. Since its founding in 1978, the firm has adhered to the same core principles: supporting its entrepreneurs, providing an excellent return to its limited partners, and operating in accordance with the highest standards of integrity and respect. NEA focuses on investments at all stages of a company's development, from seed stage through IPO. With approximately $8.5 billion in committed capital, NEA's experienced management team has invested in more than 550 companies, of which more than 160 have gone public and more than 230 have been acquired. NEA has U.S.-based offices in Baltimore, Maryland; Chevy Chase, Maryland; and Menlo Park, California. In addition, New Enterprise Associates (India) Pvt. Ltd. has an office in Bangalore, India and New Enterprise Associates (Beijing) Ltd. has offices in Beijing and Shanghai, China. For additional information, visit www.nea.com.
MPM Capital is one of the world's largest life science-dedicated venture investors. With committed capital under management in excess of $2.5 billion, MPM Capital is uniquely structured to invest globally in healthcare innovation. More information is available at www.mpmcapital.com.
They say the right things on Privacy:
Privacy
Privacy has become a subject of debate in today's information age. We recognize that genetic information is sensitive for many people. We believe all efforts must be made to guarantee individuals complete control over access to their genetic information.
We believe the potential benefits of sharing genetic information outweigh the privacy risks. 23andMe believes that by enabling its members to share their data, we are providing them a beneficial feature they want and are entitled to have as custodians of their own genetic information.
23andMe employs robust, multi-layered encryption and authentication methods and conducts regular audits of our methods to protect against unauthorized access to our systems. We also employ software, hardware and physical security measures to prevent unauthorized access to the computers where we store customer data.
Genetic Nondiscrimination
We believe that individuals should be protected against genetic discrimination. As part of the Genetic Alliance, we supported passage of the Genetic Information Nondiscrimination Act (GINA), which President Bush signed into law on May 21, 2008. However, genetic anti-discrimination laws vary from state to state and from country to country. Some, but not all, jurisdictions have laws that protect individuals with regard to their genetic information. We encourage our customers to understand the extent of legal protection for their genetic information before they share it with anyone.
and this lady seems to be the head honcho:
Anne Wojcicki
CEO and Co-Founder
Anne co-founded 23andMe in 2006 after a decade spent in healthcare investing, focused primarily on biotechnology companies. Her hope was to empower consumers with access to their own genetic information and to create a way to generate more personalized information so that commercial and academic researchers could better understand and develop new drugs and diagnostics. Presently, 23andMe has built one of the world's largest databases of individual genetic information. Its novel, web-based research approach allows for the rapid recruitment of participants to many genome-wide association studies at once, reducing the time and money needed to make new discoveries, and the company has created a proven and standardized resource for finding new genetic association and confirming genetic loci discovered by others. Under Anne's leadership 23andMe has made significant advances in bringing personalized medicine directly to the public. Anne graduated from Yale University with a BS in Biology. Getting access to and understanding her own genetic information had always been one of her ambitions.